IMAC (IMAC) Competitors $0.09 +0.01 (+10.41%) As of 08/21/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFDA EventsHeadlinesSEC FilingsTrendsBuy This Stock IMAC vs. OBSV, EKSO, CYCN, BIAF, AEON, GNPX, HSCS, NLSP, BMRA, and KPRXShould you be buying IMAC stock or one of its competitors? The main competitors of IMAC include ObsEva (OBSV), Ekso Bionics (EKSO), Cyclerion Therapeutics (CYCN), bioAffinity Technologies (BIAF), AEON Biopharma (AEON), Genprex (GNPX), HeartSciences (HSCS), NLS Pharmaceutics (NLSP), Biomerica (BMRA), and Kiora Pharmaceuticals (KPRX). These companies are all part of the "medical" sector. IMAC vs. Its Competitors ObsEva Ekso Bionics Cyclerion Therapeutics bioAffinity Technologies AEON Biopharma Genprex HeartSciences NLS Pharmaceutics Biomerica Kiora Pharmaceuticals ObsEva (NASDAQ:OBSV) and IMAC (NASDAQ:IMAC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, risk, dividends, earnings, analyst recommendations, institutional ownership and media sentiment. Do institutionals & insiders believe in OBSV or IMAC? 17.5% of ObsEva shares are owned by institutional investors. Comparatively, 24.3% of IMAC shares are owned by institutional investors. 14.4% of ObsEva shares are owned by insiders. Comparatively, 10.0% of IMAC shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Does the media prefer OBSV or IMAC? In the previous week, IMAC had 1 more articles in the media than ObsEva. MarketBeat recorded 1 mentions for IMAC and 0 mentions for ObsEva. IMAC's average media sentiment score of 0.48 beat ObsEva's score of 0.00 indicating that IMAC is being referred to more favorably in the news media. Company Overall Sentiment ObsEva Neutral IMAC Neutral Which has better earnings and valuation, OBSV or IMAC? IMAC has higher revenue and earnings than ObsEva. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioObsEvaN/AN/A-$58.38M-$0.92N/AIMAC$15.22M0.15-$10.54MN/AN/A Is OBSV or IMAC more profitable? ObsEva has a net margin of 0.00% compared to IMAC's net margin of -75.40%. IMAC's return on equity of -52.17% beat ObsEva's return on equity.Company Net Margins Return on Equity Return on Assets ObsEvaN/A -416.36% -92.01% IMAC -75.40%-52.17%-34.51% Which has more volatility and risk, OBSV or IMAC? ObsEva has a beta of 0.68, indicating that its stock price is 32% less volatile than the S&P 500. Comparatively, IMAC has a beta of -0.88, indicating that its stock price is 188% less volatile than the S&P 500. SummaryIMAC beats ObsEva on 7 of the 10 factors compared between the two stocks. Get IMAC News Delivered to You Automatically Sign up to receive the latest news and ratings for IMAC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMAC vs. The Competition Export to ExcelMetricIMACSpecialty Outpatient Clinics IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.33M$1.57M$5.76B$9.58BDividend YieldN/AN/A4.41%4.10%P/E RatioN/AN/A31.1026.05Price / Sales0.150.15433.22103.03Price / CashN/AN/A37.7358.48Price / Book0.130.139.536.61Net Income-$10.54M-$10.54M$3.26B$265.56M7 Day PerformanceN/AN/A2.10%1.97%1 Month PerformanceN/AN/A2.81%-0.36%1 Year PerformanceN/AN/A30.56%19.03% IMAC Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMACIMACN/A$0.09+10.4%N/A-95.1%$2.33M$15.22M0.00106Gap DownOBSVObsEvaN/AN/AN/AN/A$7.94MN/A0.0050Gap DownEKSOEkso Bionics1.7103 of 5 stars$3.04+2.0%$562.50+18,403.3%-98.3%$7.93M$17.92M-0.4660Positive NewsCYCNCyclerion Therapeutics1.5748 of 5 stars$2.38+9.4%N/A-4.4%$7.93M$2M-3.2130Positive NewsShort Interest ↓BIAFbioAffinity Technologies0.5242 of 5 stars$0.27-1.8%N/A-85.4%$7.80M$9.36M-0.3810Gap UpAEONAEON Biopharma2.9126 of 5 stars$0.69+5.0%$360.00+52,134.5%-98.9%$7.79MN/A3.835Gap DownGNPXGenprex1.6224 of 5 stars$0.23+10.2%N/A-76.0%$7.77MN/A0.0020Gap UpHSCSHeartSciences3.2773 of 5 stars$3.39-9.1%$13.00+283.5%+5.8%$7.73MN/A-0.3610Positive NewsHigh Trading VolumeNLSPNLS PharmaceuticsN/A$2.13+2.4%N/A+1,379.2%$7.67MN/A0.006Short Interest ↓BMRABiomerica0.5008 of 5 stars$2.99-0.8%N/A-0.1%$7.61M$5.41M-1.2960Positive NewsUpcoming EarningsShort Interest ↓KPRXKiora Pharmaceuticals2.7814 of 5 stars$2.50+2.0%$10.00+300.0%-26.2%$7.60M$16.02M-0.8610Gap Up Related Companies and Tools Related Companies ObsEva Competitors Ekso Bionics Competitors Cyclerion Therapeutics Competitors bioAffinity Technologies Competitors AEON Biopharma Competitors Genprex Competitors HeartSciences Competitors NLS Pharmaceutics Competitors Biomerica Competitors Kiora Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMAC) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IMAC Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IMAC With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access